c19early.org COVID-19 treatment researchCOVID-19 treatments

DFV890 for COVID-19: real-time analysis

c19early.org
DFV890 for COVID-19
1 study with 142 patients
Serious outcome risk
DFV890
Control
No significant improvements are seen in meta-analysis to date.
COVID-19 DFV890 studies · November 2026
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−3%
Mortality (1)−3%
RCTs (1)−3%
Late (1)−3%
00.511.5+
← DFV890
reduces riskIncreased
risk →
Sep 14
2022
 Madurka et al., Infection, doi:10.1007/s15010-022-01904-w DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
3% higher mortality (p=1) and 1% worse recovery (p=0.95). RCT 143 hospitalized patients with COVID-19 pneumonia showing no significant difference in APACHE II scores with DFV890 (NLRP3 inhibitor).